Dr. Tashko’s Key Clinical Trials
Higher Dose Nattokinase for Plaque and Cholesterol
This article explains how higher dose nattokinase supports plaque stability and improves cholesterol patterns in a large clinical study of 1,062 adults. It reviews lipid changes, carotid ultrasound findings, lifestyle interactions, and factors that strengthen results. It also highlights the importance of proper dosing and the need for medical supervision as nattokinase influences clot balance and may interact with other cardiovascular therapies.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, Heart Health, Insights from Dr. Tashko, Lipid Health
Stem Cell–Derived Islets: A Breakthrough Step Toward Insulin Independence in Type 1 Diabetes
A new NEJM study reveals that stem cell–derived islet therapy, zimislecel (VX-880), restored insulin production in patients with type 1 diabetes. All participants achieved glucose stability, and most became insulin-independent within one year. This advance signals a breakthrough in regenerative medicine and a step closer to a functional cure for diabetes.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, Insights from Dr. Tashko, Pancreas Health
Steps and Health: What the New Lancet Meta-Analysis Reveals
A new Lancet Public Health study confirms that walking around 7,000 steps a day can substantially reduce the risk of early death, heart disease, diabetes, and dementia. The findings highlight that meaningful benefits begin even at 3,000 to 4,000 steps, offering hope to less active adults. Regular movement throughout the day proves more important than perfection, turning step counting into a powerful, evidence-based health strategy.
Published
GLP-1 Agonists and Pancreatitis Risk: Reassessing an Old Concern with New Evidence
Modern data confirm GLP-1 agonists are not linked to pancreatitis. Studies from 2025 show no increase in risk and, in some cases, lower recurrence rates and mortality. These findings overturn old concerns and highlight how improved metabolic control may protect the pancreas. Clinicians can now use GLP-1s more confidently as part of holistic, individualized care for diabetes and obesity.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Insights from Dr. Tashko, Pancreas Health
Oral Semaglutide 25 mg and Orforglipron for Obesity: New NEJM Insights
Three new NEJM trials highlight the potential of oral GLP-1 therapies for obesity and diabetes. Oral semaglutide 25 mg and orforglipron both achieved double-digit weight loss, far greater than Rybelsus 14 mg. Results from the OASIS-4, ATTAIN-1, and ACHIEVE-1 studies suggest next-generation oral medications may soon rival injectables. These may give patients more flexible, effective, and convenient options for long-term weight management and metabolic health.
Published
MariTide vs Tirzepatide: Similarities and Differences
MariTide and tirzepatide are changing obesity treatment. Both target gut hormones to support weight loss, yet they act differently. Tirzepatide is already approved as a weekly injection, while MariTide is still in trials as a monthly option. Patients may soon have more tailored choices for appetite control and metabolic health.
Published
Once-Monthly MariTide Shows Promise for Weight Loss
MariTide, a once-monthly obesity treatment studied in NEJM, achieved 12–16% weight loss in participants without diabetes and up to 12% in those with diabetes. Patients also saw lower blood sugar levels. Side effects were mostly gastrointestinal and improved with dose escalation. At our Maryland practice, we offer comprehensive obesity and diabetes care, helping patients explore advanced therapies with a balanced viewpoint and personalized care.
Published
CagriSema in Clinical Trials: What Patients Should Know
Two NEJM trials highlight CagriSema, a combination of cagrilintide and semaglutide, as a promising investigational therapy. Patients experienced weight loss exceeding semaglutide alone, with results comparable to tirzepatide. While not FDA approved, the research suggests CagriSema may offer a future option for obesity and diabetes management.
Published
Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care
Retatrutide is a triple hormone agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trials show up to 24% weight loss, major A1c reduction, and liver fat improvement. This blog reviews trial findings and explains how they may influence our holistic, individualized approach to obesity and diabetes in Montgomery County, Maryland and beyond.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, Insights from Dr. Tashko, Obesity Care, Weight Loss
Lower LDL Cholesterol May Protect the Brain from Dementia
A New Look at LDL and Cognitive Health We often hear about bad cholesterol—low-density lipoprotein cholesterol (LDL-C)—as a major cause of heart disease. But what about its role in brain health? A new study from a large university hospital network in South Korea helps clarify the link between LDL-C levels and dementia risk. The results are both surprising and reassuring. The Study at a Glance Researchers analyzed data from 11 university hospitals using a shared…
Published
A New Way to Lower Lipoprotein(a): What Patients Should Know
Lipoprotein(a), or Lp(a), is a cholesterol-like particle made in the liver. Unlike LDL or “bad” cholesterol, Lp(a) levels are mostly inherited. You can have high levels even with a healthy lifestyle. Researchers have now tested a new treatment called lepodisiran, an investigational small interfering RNA therapy. It’s designed to block the liver from making Lp(a). The results are promising.
Published
Lipid Changes After Alcohol Cessation: What You Need to Know
A recent study, published in JAMA Network Open in March 2025, examined how changes in alcohol consumption affect cholesterol levels. Researchers analyzed over 57,000 adults undergoing annual health checkups and found that quitting alcohol led to increased LDL (bad cholesterol) and decreased HDL (good cholesterol).
Published